Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Euronet Worldwide Fourth Quarter 2025 Earnings Call - Tough Quarter, But Management Sees 10%-15% EPS Growth in 2026 Driven by Digital Push and EFT Strength
Euronet reported a challenging Q4 2025, hit by immigration-policy uncertainty and economic stress among lower-income consumers that pressured money transfer and epay. Despite that, the company posted ...
- Q4 2025 was one of the more challenging operating quarters in recent memory, with immigration policy uncertainty and economic stress weighing most heavily on money transfer and epay.
- Management remains confident, forecasting adjusted EPS growth of 10% to 15% for 2026 and pointing to multiple levers to drive upside as volumes normalize and investments scale.
- Q4 adjusted EPS was $2.39; full-year adjusted EPS was $9.61, representing the company’s fifth consecutive year of double-digit adjusted EPS growth.
- +15 more takeaways
Conduent Q4 2025 Earnings Call - New CEO Launches Turnaround: Speed, Cost Cuts, Portfolio Sales to Restore Free Cash Flow
Newly installed CEO Harsha Agadi used his first public quarterly call to frame Conduent as a turnaround. He laid out six immediate priorities: move faster, apply strict capital discipline, cut corpora...
- New CEO Harsha Agadi has been on the job less than 30 days and declared Conduent a turnaround, announcing six priorities: speed, financial discipline, cost reduction, portfolio rationalization, pipeline conversion, and organizational simplification.
- Qualified ACV pipeline stands at $3.2 billion, up 4% year-over-year, and management emphasized converting pipeline to revenue rather than just building it.
- Quarterly new business ACV was $152 million, one of the strongest quarters recently, and full year 2025 new business ACV was $517 million, up 6% versus 2024.
- +14 more takeaways
AB InBev Full Year 2025 Earnings Call - Strategy Delivered EPS, Margin and Cash Growth Despite Volume Weakness
AB InBev closed 2025 with a familiar-but-uneven picture: volumes lagged, but disciplined revenue management, premiumization and productivity drove dollar EPS, EBITDA and margin expansion. The group re...
- Company delivered another year of dollar EPS growth, with underlying EPS of $3.73, up 6% in U.S. dollars and 9.4% in constant currency.
- EBITDA increased 4.9% year-over-year and margins expanded by 101 basis points, driven by disciplined revenue management and productivity gains.
- Free cash flow stayed around the prior-year level of $11.3 billion, enabling $3.2 billion of completed buybacks, a further $6 billion buyback program in execution, and a proposed final dividend that, combined with the interim dividend, raises payouts 15% year-over-year.
- +12 more takeaways
SCI Fourth Quarter 2025 Earnings Call - Insurance Shift Increases GA Revenue, Pressures Near-Term Margins; 2026 EPS Guide $4.05-$4.35
SCI closed 2025 with modest top-line gains, stronger cash flow, and an operational pivot that will shape 2026. Q4 adjusted EPS was $1.14, up 8% year over year, and full-year adjusted EPS was $3.85, up...
- Q4 2025 adjusted EPS was $1.14, up 8% from $1.06 a year earlier; full-year adjusted EPS was $3.85, up 9% versus 2024.
- 2026 normalized EPS guidance range is $4.05-$4.35, midpoint $4.20, implying 5%-13% growth, with management midpoint assumptions focused on sales momentum and cost control.
- Adjusted operating cash flow for full-year 2025 was $966 million; Q4 adjusted operating cash flow was $213 million, above guidance.
- +16 more takeaways
IFF Q4 and Full Year 2025 Earnings Call - Food Ingredients Sale Launched, Focus Shifts to High-Value Taste, Scent and Health
IFF closed 2025 with steady execution but a clear strategic pivot. Q4 revenue was nearly $2.6 billion, up 1% year over year, and EBITDA was $437 million, up 7% with margin expansion to 16.9%. The comp...
- IFF launched a formal, competitive sale process for its food ingredients business two weeks ago, after earlier divestitures of Pharma Solutions, Nitrocellulose, and Renee Laurent, and an agreement to sell soy crush, concentrates and lecithin to Bunge expected by April.
- Q4 revenue was nearly $2.6 billion, up 1% year over year against a 6% prior-year comparable; two-year average sales growth was about 4%.
- Q4 EBITDA totaled $437 million, up 7% year over year, and consolidated EBITDA margin expanded 90 basis points to 16.9%.
- +11 more takeaways
Pilgrim's Pride Q4 FY2025 Earnings Call - Branded momentum and heavy CapEx to blunt regional weakness
Pilgrim’s Pride closed fiscal 2025 with $18.5 billion in revenue and $2.27 billion of Adjusted EBITDA, highlighting momentum in branded prepared foods, led by Just BARE, and operational gains in the U...
- Fiscal 2025 revenue $18.5 billion; Adjusted EBITDA $2.27 billion, with an Adjusted EBITDA margin around 12.3% for the year.
- Q4 2025 net revenue $4.52 billion; management reported Q4 Adjusted EBITDA of $415.1 million and a 9.2% margin.
- U.S. business: FY net revenue $11.0 billion; U.S. Adjusted EBITDA $1.63 billion and a 14.8% margin, driven by fresh retail, QSR wins, and Big Bird operational improvements.
- +12 more takeaways
Materion Fourth Quarter 2025 Earnings Call - Quality Pause Hits Q4 but Semiconductor and Optics Momentum Powers 2026 Upside
Materion closed 2025 with a messy but fixable finale. A control failure in Precision Clad Strip forced a temporary shutdown of two facilities, subtracting from Q4 sales and cash flow. Excluding that e...
- Precision Clad Strip quality event halted production at two facilities in Q4 after a control failure produced non-conforming material discovered by the customer, temporarily stopping shipments and receipts.
- Management implemented root-cause fixes and a revised, more robust plant-wide quality system, customer visits occurred, and both facilities were brought back online late in the quarter and are ramping into Q1.
- Excluding the clad strip event, Q4 organic Value-Added Sales grew 7% year-over-year; overall Q4 Value-Added Sales were $253.9 million (excluding pass-through precious metals).
- +12 more takeaways
Rollins, Inc. Fourth Quarter 2025 Earnings Call - Recurring Growth Holds at 7%+, One-Time Sales Hit by Weather; 2026 Organic Guide 7%-8%
Rollins closed 2025 at $3.8 billion in revenue with double-digit revenue, earnings, and cash flow growth for the year, even as Q4 softened. Management pins the weakness to early winter weather in the ...
- Rollins reached $3.8 billion in revenue for fiscal 2025 and delivered double-digit revenue, earnings, and cash flow growth for the year.
- Organic growth for 2025 was 6.9% for the full year; management anchors 2026 organic guidance at 7%-8% plus 2%-3% from M&A.
- Recurring revenue and ancillary services, which represent over 80% of revenue, grew above 7% in Q4 and for the year, and are the primary metric management uses to judge health.
- +12 more takeaways
Alnylam Pharmaceuticals Q4 and Full Year 2025 Earnings Call - AMVUTTRA Launch Drives Nearly $3B Revenue and GAAP Profitability
Alnylam closed 2025 as a different company than it entered. The AMVUTTRA ATTR cardiomyopathy launch powered an 81% year-over-year jump in combined net product revenues to nearly $3.0 billion, and the ...
- AMVUTTRA ATTR cardiomyopathy launch propelled 2025: combined net product revenues nearly $3.0 billion, up 81% versus 2024, with Q4 product sales of $995 million.
- Alnylam achieved GAAP and non-GAAP profitability in Q4 and for full-year 2025, a stated milestone after executing on the Alnylam Fit by 2025 goals.
- TTR franchise drove the year: full-year TTR sales more than doubled, Q4 TTR revenue was $858 million, and TTR is expected to remain the primary growth engine in 2026.
- +12 more takeaways
Zoetis Q4 2025 and Full Year 2025 Earnings Call - 2026 guidance tempered as U.S. weakness and competition offset portfolio strength
Zoetis closed 2025 with resilient top-line and margin performance, but the path forward is bumpier than the headline numbers suggest. Full-year organic operational revenue rose 6% to $9.5 billion, adj...
- Full-year 2025 organic operational revenue rose 6%, with reported revenue of $9.5 billion and adjusted net income of $2.8 billion, up 7% on an organic operational basis.
- Management guided 2026 to 3%-5% organic operational revenue growth, and 3%-6% organic operational adjusted net income growth; reported revenue guidance is $9.825 billion to $10.025 billion.
- Price accounted for most of 2025 growth, with 4 percentage points from price and 2 points from volume; management expects normal price increases of roughly 2%-3% in 2026.
- +12 more takeaways